|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Multidisciplinary Care, Early Detection, and Ongoing Prostate Cancer Challenges
|
Maha Hussain, MD, FACP, FASCO
Maha Hussain speaks with Phillip Koo about advances in prostate cancer diagnostics and therapeutics. Dr. Hussain emphasizes critical unmet needs including better understanding of resistance mechanisms, detection of micrometastatic disease, and equitable access to care, noting that early detection and follow-up remain essential for optimal outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular Management in Advanced Prostate Cancer
|
Zeynep Irem Ozay, MD
Neeraj Agarwal speaks with Zeynep Ozay about research on the impact of statins in patients with advanced prostate cancer treated with apalutamide. Dr. Ozay shares findings from a pooled patient-level analysis of the TITAN and SPARTAN trials, which included 2,190 patients receiving either ADT alone or ADT plus apalutamide.
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs
|
|
Daniel Joyce, MD, MS
|
| Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly for commercially insured patients.
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical Outcomes Among Patients with mHSPC in Contemporary Real-World US Clinical Practice: A Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis
|
| A. Oliver Sartor, MD
|
| In this real‑world PRECISION analysis of 43,415 US patients with mHSPC diagnosed from 2020–2025, about half still received ADT alone, one‑half doublet therapy, and only 2.5% triplet therapy, despite guideline support for treatment intensification. Doublet and triplet regimens were associated with significantly longer castration resistance‑free survival than ADT monotherapy, and triplet therapy showed the longest overall survival, reinforcing the need to expand use of intensified systemic therapy beyond ADT alone in routine practice.
|
|
|
|
|
|
| Treatment Utilization Among Patients with mHSPC in Real-World US Settings: A Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis
|
| Daniel George, MD
|
| Daniel George presents the PRECISION database analysis of 43,415 US patients with mHSPC diagnosed 2020–2025, nearly 40% still received ADT monotherapy across their disease course, while 57% received doublet and only about 4% received triplet therapy, despite guideline recommendations for early treatment intensification.
|
|
|
|
|
|
|
|
|
|
|
| Real-World Effectiveness of Systemic Therapies After 177Lu-PSMA-617 Treatment in Patients with mCRPC: A Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis
|
| Xiao Wei, MD, MAS
|
| In this PRECISION real‑world cohort of 442 patients with mCRPC who received systemic therapy after 177Lu‑PSMA‑617, nearly half still achieved a PSA50 response and median progression‑free and overall survival of about 9 and 10 months, respectively, indicating meaningful activity of post‑radioligand systemic treatments.
|
|
|
|
|
|
| Harnessing Caregiver Support to Improve Shared Decision-Making in Metastatic Prostate Cancer Treatment: A US-Based Quantitative Survey
|
| Daniel George, MD
|
| This US survey of 230 caregivers of men with metastatic prostate cancer found that caregivers are deeply integrated into care—most attend visits, provide emotional support, help manage medications, and actively participate in treatment decisions. Yet nearly a quarter feel under‑supported and more than half worry that appropriate resources do not exist, with women disproportionately bearing the emotional and symptom‑monitoring load, highlighting the need for targeted education and psychosocial support to fully harness caregiver involvement in shared decision‑making.
|
|
|
|
|
|
|
|
|
|
|
